OncoMatch

OncoMatch/Clinical Trials/NCT06641635

Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer

Is NCT06641635 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Moderated hypofractionated online adaptive radiotherapy and Conventional radiotherapy for cervical cancer.

Phase 3RecruitingPeking Union Medical College HospitalNCT06641635Data as of Jun 2026Location: China

Treatment: Moderated hypofractionated online adaptive radiotherapy · Conventional radiotherapyThe most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Moderated hypofractionated online adaptive radiotherapyConventional radiotherapy

Cancer type

Cervical Cancer

Disease stage

Required: Stage IB, IIA, IIB, IIIA, IIIB, IIIC1

Excluded: Stage IA, IIIC2, IVA, IVB

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75
Female only

Prior therapy

Cannot have received: surgery

Exception: pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization

Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization

Cannot have received: abdominal or pelvic radiotherapy

History of prior abdominal or pelvic radiotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06641635 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior surgery, abdominal or pelvic radiotherapy disqualifies patients from enrollment.

What disease stage is eligible?

Stage IB or IIA or IIB or IIIA or IIIB or IIIC1 is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify